Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Accounting for the Impact of EGPA on Patient Quality of Life

Premiere Date: Thursday, December 29, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, December 29, 2023


Michael E. Wechsler, MD, MMScMichael E. Wechsler, MD, MMSc (Moderator)
Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine
Director, The Cohen Family Asthma Institute
National Jewish Health
Denver, CO

Jennifer Gordon, PhDJennifer Gordon, PhD 
Patient Partner, Vasculitis Foundation
Co-Principal Investigator, Vasculitis Patient Powered Research Network
Kansas City, MO

Statement of Need

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of vasculitis that often goes unrecognized or misdiagnosed. Patients with EGPA go an average of 4 years between initial symptom onset and diagnosis. Clinicians fail to recognize early, non-specific symptoms of EGPA, delaying treatment that could prevent eosinophil-mediated organ damage. Patients with EGPA are frequently treated with corticosteroids which can result in adverse events that compound the impact of the disease. Newer treatments targeting IL-5 and eosinophil activity may allow for corticosteroid tapering or discontinuation and improvement in patient quality of life. Clinicians should utilize shared decision making to develop treatment plans that prioritize patient-centered goals for managing disease symptoms and minimizing medication toxicity.

Dr. Jennifer Gordon was diagnosed with EGPA in 2014 and is the Vasculitis Patient Powered Research Network (VPPRN) Co-Principal Investigator and co-Lead Patient-Partner in the EGPA Registry. During this 30-minute CMEO Snack, Dr. Gordon will join Dr. Michael Wechsler, a national expert in EGPA. They will discuss how EGPA impacts patient quality of life and how clinicians can better detect and manage hidden symptoms of disease. Patient perspectives on delayed diagnosis, disease impact on their daily functioning, treatment options, and chronic steroid use will be included in the discussion.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Assess how EGPA and associated conditions impact patient QoL.

Financial Support

This educational activity is supported by an educational grant from GSK.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in rheumatology, allergy/immunology, pulmonology, nephrologist, internal medicine, and primary care medicine.

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Wechsler reports the following financial relationships:

Advisory Board/Consultant: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Cerecor Inc.; Cohero Health, Inc.; CytoReason LTD; Eli Lilly and Company; Equillium Bio; GSK; Incyte; Kinaset Therapeutics; Novartis Pharmaceuticals Corporation; Om Pharma; Phylaxis Bioscience, LLC; PULMATRiX, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Restorbio; Roche/Genentech, Inc.; Sanofi/Genzyme.; Sentien Biotechnologies, Inc.; Sound Biologics; Tetherex Pharmaceuticals; Teva Pharmaceuticals USA, Inc.; and Upstream Bio

Research Support: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi/Genzyme

Speakers Bureau: AstraZeneca; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi

Dr. Gordon reports the following financial relationships:

Consultant/Employee/Stock Options: Excision BioTherapeutics, a biotech start-up company developing gene editing technology for the treatment of infectious disease. This relationship is unrelated to this CE activity.

The following peer reviewer and CME Outfitters staff have no financial relationships:
  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Thomas Mitchell (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download